Avsar.

Healthcare · Pharmaceuticals

Shilpa Medicare Ltd (SHILPAMED)

₹955.60

Mkt cap
₹18,690 Cr
P/E ratio
65.70
P/B
7.24
Div yield
0.06%
ROE
8.99%
ROCE
10.90%
EPS (TTM)
₹14.54
Book value
₹132
52W range
260–1,095
Sector
Healthcare

Price history

Previous close

Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]

NSE SHILPAMEDBSE 530549
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−12.73% from high
₹956
₹260+268.25% from low₹1,095
Current
₹955.60
Prev close
₹935.60
Day
+2.14%
Price performance
1D
+2.61%
1W
+11.07%
1M
−9.07%
3M
+59.22%
6M
+137.59%
1Y
+162.15%
YTD
+198.81%

Financials

Revenue, profit & margin
P/E ratio
65.7×
SHILPAMED is 91% above the sector median of 34.4×
SHILPAMED65.7×
Sector median34.4×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales260313287292293344319331321370410437466
Expenses214255222222222258239252231262296317330
Operating Profit465865707086817991108114120136
OPM %18%19%23%24%24%25%25%24%28%29%28%27%29%
Other Income22291052-2162-13459
Interest18232624242612141916111412
Depreciation27282727272829292930303135
Profit before tax3914282937421550646112098
Tax %64%83%67%12%51%51%24%5%5%32%27%10%-3%
Net Profit1252414183215474445108101
EPS in Rs0.070.090.261.410.720.921.620.742.402.252.285.515.16
Raw PDF

Earnings

Results dates & reactions
Next results
5 Nov '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +11.96% · closed higher next day 1 of last 1
 Q1FY27
Broadcast5 Aug '26
Earnings day+11.96%
+1 day+14.60%
+5 days+24.90%
+15 days+33.52%
+30 days+48.66%
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
40.13%Promoter
Promoters40.13%
FIIs12.11%0.72
DIIs8.26%0.21
Public39.49%0.93
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,777.7034.664,26,5300.90%1,995−10.53%16,199+11.88%20.53%
Divi's Lab.₹9,780.0087.142,59,6280.31%902+65.50%3,080+27.80%21.97%
Torrent Pharma.₹4,613.4080.831,75,4790.82%534−10.03%4,979+50.79%15.19%
Laurus Labs₹2,405.5097.001,29,9720.08%436+126.43%2,206+33.44%17.76%
Zydus Lifesci.₹1,245.5025.521,24,2390.08%990−35.09%8,017+21.96%21.14%
Dr Reddy's Labs₹1,352.0040.301,12,8490.59%913−31.35%8,698−1.48%13.04%
Cipla₹1,378.9035.871,11,3970.94%852−35.05%7,404−2.44%15.49%
Shilpa Medicare₹955.6065.7318,6900.06%101+115.14%466+44.90%10.88%
Median: 158 Co.₹426.3834.391,9210.08%14+22.08%175+18.92%15.12%

Filings

Annual reports15
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022Annual Report 2021Annual Report 2020Annual Report 2019Annual Report 2018Annual Report 2017Annual Report 2016Annual Report 2015Annual Report 2014Annual Report 2013Annual Report 2013
Concall transcripts57
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJul 2024
Credit ratings6
Rating update 6 JulfitchRating update 1 Jul 2025fitchRating update 2 Jul 2024fitchRating update 23 Nov 2023fitchRating update 22 Sep 2023fitchRating update 25 Jul 2023fitch
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 29 Oct - Investor conference call for Q2-FY27 is scheduled to be held on 05 November 2026.Board Meeting Intimation for Approval Of Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30 September, 2026. 29 Oct - Board meets 5 Nov 2026 to consider Q2 and H1 FY2026-27 unaudited results; trading window closed till 7 Nov.Europe GMP Approval Of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana. 10 Oct - Unit 4, Jadcherla received Europe GMP certification after AGES Austria inspection.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - Submitted Regulation 74(5) compliance certificate for quarter ended September 30, 2026.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 26 Sep